Evolution of multiple sclerosis treatment: Next generation therapies meet next generation efficacy criteria

The Lancet Neurology

Volumn 10, Issue 4, 2011, Pages 293-295

  Hartung, Hans Peter ^a   Aktas, Orhan ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; GLATIRAMER; NATALIZUMAB;

DISABILITY; DISEASE ACTIVITY; INFLAMMATION; LETTER; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

HUMANS; MULTIPLE SCLEROSIS;

EID: 79952736410     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70043-6     Document Type: Letter

References (10)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
2. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009, 8:254-260.
3. Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 2011, published online Mar 11. 10.1016/S1474-422(11)70023-0.
4. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011, published online Mar 11. 10.1016/S1474-4422(11)70020-5.
5. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010, 362:416-426.
6. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
7. Aktas O, Kieseier B, Hartung HP Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010, 33:140-152.
8. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
9. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
10. Hartung HP, Aktas O Oral therapies for multiple sclerosis: are we there yet?. Lancet Neurol 2010, 9:454-457.